Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SAN DIEGO--Genta Jago, a joint venture between Genta Incorporated and Jagotec AG (Hergiswil, Switzerland), has filed an Investigational New Drug application with the FDA for a controlled-release formulation of zidovudine (AZT), marketed

SAN DIEGO--Genta Jago, a joint venture between Genta Incorporatedand Jagotec AG (Hergiswil, Switzerland), has filed an InvestigationalNew Drug application with the FDA for a controlled-release formulationof zidovudine (AZT), marketed by Burroughs Wellcome Co. as Retrovir.

The recommended dosage for AZT in the United States is six timesdaily. Results of pilot in vitro and human pharmacokinetic studiesin Europe suggest that once- or twice-daily dosing may be possiblewith the controlled-release formulation, which incorporates Jagotec'sGeomatrix delivery technology.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.